Opko Health, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Opko Health, Inc. - overview
Location
Miami, FL, US
Primary Industry
Healthcare
About
Opko Health, Inc. is a healthcare company focused on developing innovative diagnostic and therapeutic solutions for serious diseases, enhancing patient care through advanced medical technologies. Opko Health, Inc. operates as a fully-integrated healthcare company that develops and commercializes innovative diagnostics and therapeutics.
Founded by Fuad Fares, the company is headquartered in Miami, US, and has undergone strategic pivots to expand its core offerings. Currently, Charles Bishop serves as the CEO. The company has evolved through various stages of funding, securing significant investments to support its growth. OPKO Health, Inc.
specializes in innovative healthcare solutions with key products including NGENLA™, a next-generation human growth hormone therapy for pediatric growth hormone deficiency, and RAYALDEE®, aimed at treating secondary hyperparathyroidism in chronic kidney disease patients. These therapies are marketed globally, supported through partnerships like the one with Pfizer, catering to hospitals and healthcare providers in the US, Europe, and selected Asian regions. In the most recent fiscal year 2024, Opko Health, Inc. reported revenue of USD 713.
14 mn and an EBITDA of USD -51. 92 mn, reflecting its financial performance through its pharmaceutical products and diagnostic services. Opko Health plans to leverage recent funding to enhance its product pipeline, with developments aimed at launching new therapies for growth hormone deficiencies and chronic kidney disease by 2025. The company also looks to expand its market presence in Europe and Asia, targeting specific growth in underserved regions.
The funding will facilitate research and development initiatives, ensuring a focus on innovative healthcare solutions.
Primary Industry
Healthcare
Sub Industries
Healthcare, Medical Devices & Equipment, Pharmaceuticals
Website
www.opko.com
Total Amount Raised
Subscriber access only
Opko Health, Inc. - timeline of key events
Opko Health, Inc. - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 91,125,000 | 491,738,000 | 1,221,661,000 | 1,067,503,000 | 990,266,000 | 901,935,000 | 1,435,413,000 | 1,774,718,000 | 1,004,196,000 | - | - | - |
| % Revenue Growth (YoY) | - | 439.6% | 148.4% | (12.6%) | (7.2%) | (8.9%) | 59.1% | 23.6% | (43.4%) | - | - | - |
| EBITDA (USD) | (128,881,000) | (55,021,000) | 23,538,000 | (177,745,000) | (73,666,000) | (179,250,000) | 143,923,000 | 98,251,000 | (116,437,000) | - | - | - |
| Operating Income (USD) | (145,815,000) | (98,481,000) | (73,275,000) | (280,062,000) | (171,197,000) | (274,052,000) | 57,714,000 | 18,750,000 | (226,253,000) | - | - | - |
| Operating Margin | (160.0%) | (20.0%) | (6.0%) | (26.2%) | (17.3%) | (30.4%) | 4.0% | 1.1% | (22.5%) | - | - | - |
| % EBITDA Margin | (141.4%) | (11.2%) | 1.9% | (16.7%) | (7.4%) | (19.9%) | 10.0% | 5.5% | (11.6%) | - | - | - |
| NET Income (USD) | (174,638,000) | (31,428,000) | (25,083,000) | (308,870,000) | (153,040,000) | (314,925,000) | 30,586,000 | (30,143,000) | (328,405,000) | - | - | - |
| % Net Margin | (191.6%) | (6.4%) | (2.1%) | (28.9%) | (15.5%) | (34.9%) | 2.1% | (1.7%) | (32.7%) | - | - | - |
Opko Health, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.